Literature DB >> 25494248

High-risk histomorphological features in retinoblastoma and their association with p53 expression: An Indian experience.

Rao Seema1, Sobti Parul, Khurana Nita.   

Abstract

Introduction: Histopathological features in retinoblastoma are considered high-risk factors (HRF) for tumor progression and metastasis, thus their presence becomes an indication for adjuvant chemotherapy. Present study was undertaken to evaluate the incidence of HRF in retinoblastoma and to correlate them with p53 expression. Materials and
Methods: This was a retrospective study where 17 diagnosed cases of retinoblastoma were included. Cases were re-evaluated for various histomorphological parameters. Immuno-histochemical analysis was done with p53 antibody by Streptavidin biotin method.
Results: The patients were in the age range of 1.5-50 years. Common histological features included necrosis (70.5%), calcification (64.7%), and retinal detachment (58.8%). Incidence of various morphological parameters was anterior chamber seeding (47.2%), ciliary body involvement (29.4%), iris involvement (29.4%), choroid involvement (58.8%), scleral invasion (29.4%), extrascleral invasion (11.8%), and optic nerve infiltration (23.5%). p53 expression was present in four cases out of 13 cases (30.7%) and showed a significant association with choroid invasion (P = 0.02). Discussion: The presence of HRF should alert the physician for a possible metastasis, and such patients should be kept on regular follow-up to detect an early recurrence. p53 expression, a known poor prognostic indicator, showed significant association with choroid invasion, however, no association was seen with other HRF.
Conclusion: Histopathological HRF have significant therapeutic and prognostic implications. The incidence of HRF is higher in developing countries as patients present with a more advanced stage of disease. p53 expression is significantly associated with choroid invasion out of all HRF.

Entities:  

Year:  2014        PMID: 25494248      PMCID: PMC4290196          DOI: 10.4103/0301-4738.146747

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


  15 in total

1.  Clinicopathologic study of retinoblastoma including MIB-1, p53, and CD99 immunohistochemistry.

Authors:  C J Schwimer; R A Prayson
Journal:  Ann Diagn Pathol       Date:  2001-06       Impact factor: 2.090

2.  Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer.

Authors:  Ming Dong; Gang Ma; Wei Tu; Ke-Jian Guo; Yu-Lin Tian; Yu-Ting Dong
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

3.  Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution.

Authors:  F Khelfaoui; P Validire; A Auperin; E Quintana; J Michon; H Pacquement; L Desjardins; B Asselain; P Schlienger; P Vielh
Journal:  Cancer       Date:  1996-03-15       Impact factor: 6.860

4.  Factors influencing metastasis in retinoblastoma.

Authors:  J Hungerford
Journal:  Br J Ophthalmol       Date:  1993-09       Impact factor: 4.638

5.  [A study of expression of p53, c-myc and PCNA in retinoblastoma].

Authors:  X Yang; Z Zhang; Q Zeng
Journal:  Zhonghua Yan Ke Za Zhi       Date:  1999-07

6.  Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors.

Authors:  C L Shields; J A Shields; K Baez; J R Cater; P De Potter
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

7.  Postenucleation adjuvant therapy in high-risk retinoblastoma.

Authors:  Santosh G Honavar; Arun D Singh; Carol L Shields; Anna T Meadows; Hakan Demirci; Jacqueline Cater; Jerry A Shields
Journal:  Arch Ophthalmol       Date:  2002-07

8.  Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation.

Authors:  J E Kopelman; I W McLean; S H Rosenberg
Journal:  Ophthalmology       Date:  1987-04       Impact factor: 12.079

9.  Histopathologic risk factors in retinoblastoma in India.

Authors:  Roshmi Gupta; Geeta K Vemuganti; Vijay Anand P Reddy; Santosh G Honavar
Journal:  Arch Pathol Lab Med       Date:  2009-08       Impact factor: 5.534

10.  Histopathologic analysis of 232 eyes with retinoblastoma conducted in an Indian tertiary-care ophthalmic center.

Authors:  Jyotirmay Biswas; Dipankar Das; S Krishnakumar; Mahesh P Shanmugam
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2003 Sep-Oct       Impact factor: 1.402

View more
  6 in total

1.  High-Risk Histopathologic Features of Retinoblastoma Treated at a Tertiary Hospital in West Java, Indonesia.

Authors:  Nur Melani Sari; Regina Hadiputri; Maya Sari Kuntorini; Hasrayati Agustina; Friska Mardianty
Journal:  Ocul Oncol Pathol       Date:  2021-07-20

2.  Molecular pathologic interpretation of new retinoblastoma rosettes.

Authors:  Dipankar Das; Panna Deka; Kasturi Bhattacharjee; Manab Jyoti Barman; Harsha Bhattacharjee; Divakant Misra; Rushil Kumar Saxena; Anusuya Bhattacharyya; Apurba Deka
Journal:  Indian J Ophthalmol       Date:  2017-08       Impact factor: 1.848

3.  Clinicopathological Findings of Retinoblastoma: A 10-Year Experience from a Tertiary Hospital in Kampala, Uganda.

Authors:  James Joseph Yahaya; Belson Rugwizangoga; Alex Mremi; Asafu Munema
Journal:  J Ophthalmol       Date:  2019-06-16       Impact factor: 1.909

4.  High risk histopathological factors in retinoblastoma in upfront enucleated eyes: An experience from a tertiary care centre of Pakistan.

Authors:  Nausheen Yaqoob; Salima Mansoor; Kanwal Aftab; Bushra Kaleem; Ahmer Hamid; Saba Jamal
Journal:  Pak J Med Sci       Date:  2022-01       Impact factor: 1.088

5.  Expression of Ki67 as detected by MIB-1 and its association with histopathological high-risk factors among patients with retinoblastoma tumour: a cross-sectional study.

Authors:  Edda Am Vuhahula; Shakilu Jumanne; James Yahaya
Journal:  BMJ Open Ophthalmol       Date:  2022-09

6.  Epidemiology and clinical features of retinoblastoma: A tertiary care center's experience in India.

Authors:  Maneya Padma; Nuthan Kumar; Prerana S Nesargi; B S Aruna Kumari; L Appaji; Aarthi Viswanathan
Journal:  South Asian J Cancer       Date:  2020 Jan-Mar
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.